Literature DB >> 30747428

Metabolomic Biomarkers in Mental Disorders: Bipolar Disorder and Schizophrenia.

Melissa Quintero1, Danijela Stanisic1, Guilherme Cruz1, João G M Pontes2, Tássia Brena Barroso Carneiro Costa1, Ljubica Tasic3.   

Abstract

Psychiatric disorders are some of the most impairing human diseases. Among them, bipolar disorder and schizophrenia are the most common. Both have complicated diagnostics due to their phenotypic, biological, and genetic heterogeneity, unknown etiology, and the underlying biological pathways, and molecular mechanisms are still not completely understood. Given the multifactorial complexity of these disorders, identification and implementation of metabolic biomarkers would assist in their early detection and diagnosis and facilitate disease monitoring and treatment responses. To date, numerous studies have utilized metabolomics to better understand psychiatric disorders, and findings from these studies have begun to converge. In this chapter, we briefly describe some of the metabolomic biomarkers found in these two disorders.

Entities:  

Keywords:  Biomarkers; Bipolar disorder; Mental disorders; Metabolomics; Psychiatric illness; Schizophrenia

Mesh:

Substances:

Year:  2019        PMID: 30747428     DOI: 10.1007/978-3-030-05542-4_14

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  6 in total

1.  Assessing the Causal Effects of Human Serum Metabolites on 5 Major Psychiatric Disorders.

Authors:  Jian Yang; Bin Yan; Binbin Zhao; Yajuan Fan; Xiaoyan He; Lihong Yang; Qingyan Ma; Jie Zheng; Wei Wang; Ling Bai; Feng Zhu; Xiancang Ma
Journal:  Schizophr Bull       Date:  2020-07-08       Impact factor: 9.306

Review 2.  New Paradigms of Old Psychedelics in Schizophrenia.

Authors:  Danish Mahmood; Sattam K Alenezi; Md Jamir Anwar; Faizul Azam; Kamal A Qureshi; Mariusz Jaremko
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-23

3.  Causality of genetically determined metabolites on anxiety disorders: a two-sample Mendelian randomization study.

Authors:  Gui Xiao; Qingnan He; Li Liu; Tingting Zhang; Mengjia Zhou; Xingxing Li; Yijun Chen; Yanyi Chen; Chunxiang Qin
Journal:  J Transl Med       Date:  2022-10-20       Impact factor: 8.440

4.  Associations of C-Reactive Protein, Free Triiodothyronine, Thyroid Stimulating Hormone and Creatinine Levels with Agitation in Patients with Schizophrenia: A Comparative Cross-Sectional Study.

Authors:  Chao Li; Zhenchun Shi; Jiacui Ji; Gengyun Niu; Zengxun Liu
Journal:  Neuropsychiatr Dis Treat       Date:  2021-08-10       Impact factor: 2.570

5.  NMR Metabolomics in Serum Fingerprinting of Schizophrenia Patients in a Serbian Cohort.

Authors:  Katarina Simić; Nina Todorović; Snežana Trifunović; Zoran Miladinović; Aleksandra Gavrilović; Silvana Jovanović; Nataša Avramović; Dejan Gođevac; Ljubodrag Vujisić; Vele Tešević; Ljubica Tasić; Boris Mandić
Journal:  Metabolites       Date:  2022-07-29

6.  Plasma metabolomics of schizophrenia with cognitive impairment: A pilot study.

Authors:  Yihe Jiang; Xiujia Sun; Miaowen Hu; Lei Zhang; Nan Zhao; Yifeng Shen; Shunying Yu; Jingjing Huang; Huafang Li; Wenjuan Yu
Journal:  Front Psychiatry       Date:  2022-09-28       Impact factor: 5.435

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.